Real-world neuropsychiatric and cognitive responses to lecanemab and donanemab from subjective cognitive decline to dementia in Alzheimer's disease in China (Neuroscience 2026) - Sep 27, 2026 - Abstract #PSTR262.25 / W4; Pres time: Nov 17, 2026; 01:00 PM - 05:00 PM; Location: WCC Halls A-C; "Over 6 months, lecanemab and donanemab were associated with short-term improvement in AD-related neuropsychiatric symptoms and mild improvement or stabilization in cognitive scores among Aβ-PET-positive individuals from SCD to moderate-to-severe AD dementia, including atypical clinical phenotypes."
Clinical • Real-world • Real-world evidence • Alzheimer's Disease • CNS Disorders • Dementia • Depression • Mood Disorders • Psychiatry • APOE
|
|
Y. XU1; S. HUANG2; X. CHENG2; L. JIA3
|